Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study

Fig. 1

Patient disposition. The primary reason for not completing screening phase included: inclusion/exclusion criteria not fulfilled (n = 169), withdrawal of consent (n = 12), adverse event (n = 1), lost to follow-up (n = 1), and other (n = 8); *Four patients in each treatment group were not eligible for TP2; 2 patients in each treatment group were eligible but did not enter TP2; ETN, reference etanercept; SDZ ETN, Sandoz etanercept; TP, treatment period

Back to article page